文献速递生殖医学

复发性种植失败的定义、诊断与治疗选择:临床医生与胚胎学家的国际调查

Definition, diagnostic and therapeutic options in recurrent implantation failure: an international survey of clinicians and embryologists.
PubMed 文献 · Hum Reprod · 2021-01-01

该横断面调查于2020年5-6月通过邮件邀请8579名ESHRE成员参与,最终纳入735名临床医生和300名胚胎学家/IVF生物学家。调查显示RIF的定义、诊断检查和治疗选择在全球辅助生殖专业人员间差异很大,亟需RIF临床指南。

要点

  • 多数以三次胚胎移植失败为RIF阈值,新鲜和冻融胚胎均适用
  • 诊断共识最高的是解剖异常及输卵管积水、宫腔粘连、内膜厚度和子宫内膜异位症
  • 治疗共识最高的是孕前干预,包括BMI调整、吸烟和子宫内膜炎治疗

核心结论

  • RIF的定义、诊断检查和治疗选择在辅助生殖专业人员间差异很大,亟需RIF临床指南。

研究设计与样本

  • 2020年5-6月开展的横断面调查,邀请8579名ESHRE成员(来自6916个IVF中心)参与,最终纳入735名临床医生和300名胚胎学家或IVF生物学家。

主要发现

  • 多数以失败胚胎移植次数定义RIF,最常见阈值为三次胚胎移植(新鲜和冻融均包括)。
  • 超过三分之二考虑生活方式因素,主要是药物、吸烟和BMI。
  • 诊断检查共识最高的是解剖畸形和妇科方面,聚焦输卵管积水、宫腔粘连、内膜厚度和子宫内膜异位症。
  • 治疗共识最高的是孕前干预,包括BMI调整、吸烟和子宫内膜炎,其次是IVF过程中的治疗。

关键数值与推荐

  • RIF影响全球约10%的IVF患者。
  • 多数以三次胚胎移植失败为RIF阈值。
  • 超过三分之二考虑生活方式因素(药物、吸烟、BMI)。

临床怎么用

  • 临床医生应关注RIF定义的差异,并在实践中参考共识较高的诊断检查和治疗选择。

局限性

  • 回复率相对较低,但与其他调查相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the global variability in recurrent implantation failure (RIF) definition, investigation and therapy, currently offered to patients undergoing IVF? SUMAMRY ANSWER: Definitions, diagnostic investigations and treatments offered to RIF patients differ widely amongst assisted reproduction healthcare professionals and clinical guidelines on RIF are urgently needed. WHAT IS KNOWN ALREADY: RIF affects around 10% of patients undergoing IVF worldwide. There is no consensus on the definition of RIF, its diagnostic investigations or the therapeutic options, which leads to inconsistencies in clinical practice. STUDY DESIGN, SIZE, DURATION: A cross-sectional study of clinicians and embryologists was conducted between May and June 2020. The survey included 43 questions aimed at understanding participants' background and their current practice with regards to defining, investigating and managing RIF. The questions were designed by the European Society of Human Reproduction and Embryology (ESHRE) Special Interest Group (SIG) on implantation and early pregnancy following three consensus meetings. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 8579 ESHRE members from 6916 IVF centers were invited to participate using two global email calls based on their pre-specified interest in implantation and early pregnancy. SurveyMonkey and SPSS were used for data collection and analysis, respectively. Furthermore, differences were reported in the answers of European and non-European professionals, as well as between public and private settings and among clinicians clustered according to the average number of RIF patients treated per year. MAIN RESULTS AND THE ROLE OF CHANCE: The final data set included 735 clinicians and 300 embryologist or IVF-biologists. The majority defines RIF based on the number of failed embryo transfers (ETs) with the most common threshold adopted being three ETs both fresh and frozen. More than two-thirds take lifestyle factors into account, mainly drugs, smoking and BMI. The highest consensus on which diagnostic investigations should be performed was reached for anatomical malformations and gynecological aspects focusing on hydrosalpinx, Asherman's syndrome, endometrial thickness and endometriosis. Concerning treatment of RIF patients, the highest consensus was reached for preconceptional therapies, including BMI adjustment, smoking and endometritis followed by therapies during IVF procedures. LIMITATIONS, REASONS FOR CAUTION: The response rate was relatively low, but comparable to other surveys. WIDER IMPLICATIONS OF THE FINDINGS: A consensus on definition, diagnosis and treatment of RIF would help to reduce costly, time-consuming and poorly validated approaches. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used. B.T. received support from Bayer for Clinical trials concerning endometriosis and Ferring for clinical trials concerning ovarian stimulation. She received reimbursement for travel expenses from Astropharm, Ferring. Dr Kade and is a shareholder of Reprognostics. She is a board member of the Austrian Society for Obstetrics and Gynecology (OEGGG), the associate head of the 'Reproduktionsmedizinische Zentren Baden-Württemberg' (RZBW), a member of guideline group of the German Society for Obstetrics and Gynecology (DGGG) and an editorial board member of the following journals: American Journal of Reproductive Immunology (AJRI), Archives of Gynecology and Obstetrics. All the other authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Cimadomo D, Craciunas L, Vermeulen N, et al. Definition, diagnostic and therapeutic options in recurrent implantation failure: an international survey of clinicians and embryologists. Hum Reprod. 2021. PMID: 33313697. doi:10.1093/humrep/deaa317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。